The biological activity of novel cannabinoid-based compounds will be tested against native (unconjugated) CBD, CBG, CBDA and CBGA in functional binding, antibacterial/antifungal, and cancer proliferation assays.
Cancer proliferation assay and Cancer cell migration assay tests are planned using human breast cancer cell lines, MDA-MB-231 and MCF-7.
Pre-Clinical Animal Studies:
Polyfunctional cannabinoids efficacy alone and/or in combination therapy.
AXIM plans to conduct stage 1 animal studies with our polyfunctional cannabinoids together with several cytotoxic drugs at the TD2 facility. The purpose is to assess tumor cell survival and invasion in the presence of several cytotoxic drugs and immune checkpoint inhibitor antibodies in combination with our polyfunctional cannabinoids in two breast cancer and two pancreatic cancer cell lines.
Status: Estimated to begin third quarter, 2020.